Risk factor | ORa | 95% CL | AORb | 95% CL | ARRc | 95% CLd | |||
---|---|---|---|---|---|---|---|---|---|
Home follow-upe | 3.27 | 2.62 | 4.09 | 2.94 | 2.33 | 3.71 | 1.21 | 1.18 | 1.24 |
9 months of isoniazid | 1.50 | 1.29 | 1.74 | 0.88 | 0.73 | 1.05 | 0.97 | 0.92 | 1.01 |
Female | 1.04 | 0.89 | 1.21 | Â | Â | Â | Â | Â | Â |
Age categories: | Â | Â | Â | Â | Â | Â | Â | Â | Â |
   Age<6 | 6.80 | 4.11 | 11.25 | 5.40 | 3.19 | 9.13 | 1.07 | 1.06 | 1.08 |
   Age 6 to <18 | 2.71 | 2.23 | 3.30 | 2.64 | 2.10 | 3.32 | 1.11 | 1.09 | 1.12 |
   Age 18 to <35 | ref |  |  | ref |  |  | ref |  |  |
   Age 35 and older | 1.21 | 1.00 | 1.45 | 1.18 | 0.96 | 1.44 | 1.05 | 0.99 | 1.10 |
Patient referral reason: | Â | Â | Â | Â | Â | Â | Â | Â | Â |
   Correctional/rehabilitation | 0.23 | 0.18 | 0.31 | 0.43 | 0.32 | 0.57 | 0.59 | 0.47 | 0.71 |
   TST converters/TB contactsf | 1.30 | 0.99 | 1.70 | 1.23 | 0.93 | 1.63 | 1.04 | 0.98 | 1.10 |
   Postpartum women | 0.44 | 0.33 | 0.59 | 0.64 | 0.47 | 0.87 | 0.80 | 0.67 | 0.94 |
   TST+g from screening | ref |  |  | ref |  |  | ref |  |  |
Place of birth: | Â | Â | Â | Â | Â | Â | Â | Â | Â |
   Africa | 1.34 | 0.72 | 2.50 | 1.29 | 0.67 | 2.49 | 1.07 | 0.87 | 1.21 |
   Asia | 1.60 | 1.21 | 2.13 | 1.62 | 1.18 | 2.22 | 1.09 | 1.03 | 1.14 |
   Europe | 1.83 | 1.03 | 3.25 | 1.93 | 1.06 | 3.53 | 1.10 | 1.01 | 1.16 |
   Latin America | 1.17 | 0.91 | 1.52 | 1.25 | 0.93 | 1.67 | 1.06 | 0.98 | 1.13 |
   Unknown | 0.95 | 0.62 | 1.45 | 1.06 | 0.67 | 1.68 | 1.02 | 0.87 | 1.14 |
   USA | ref |  |  | ref |  |  | ref |  |  |